Comparison of the Reductions in LDL-C and non-HDL-C Induced by the Red Yeast Rice Extract Xuezhikang between Fasting and Nonfasting States in Patients with Coronary Heart Disease

Li-Yuan Zhu

Second Xiangya Hospital

Xing-Yu Wen

Central South University Xiangya School of Medicine

Qun-Yan Xiang

Second Xiangya Hospital

Li-Ling Guo

Second Xiangya Hospital

Jin Xu

Second Xiangya Hospital

Shui-Ping Zhao

Second Xiangya Hospital

Ling Liu (✉ feliuling@csu.edu.cn)

Second Xiangya Hospital <https://orcid.org/0000-0001-6979-701X>

Research

Keywords: nonfasting, coronary heart disease, LDL-C, non-HDL-C, Xuezhikang

Posted Date: December 16th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-126140/v1>

License: (cc) (i) This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Xuezhikang, an extract of red yeast rice, effectively lowers fasting blood lipid levels. However, the influence of Xuezhikang on the nonfasting levels of low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) has not been explored in Chinese patients with coronary heart disease (CHD).

Methods: Fifty CHD patients were enrolled and randomly divided into two groups ($n = 25$ each) to receive 1200 mg/d of Xuezhikang or a placebo for six weeks as routine therapy. Blood lipids were repeatedly measured before and after six weeks of treatment at 0, 2, 4 and 6 hour (h) after a standard breakfast containing 800 kcal and 50 g of fat.

Results: The serum LDL-C levels significantly decreased, from a fasting level of 3.88 mmol/L to nonfasting levels of 2.99, 2.83 and 3.23 mmol/L at 2, 4 and 6 h, respectively, after breakfast ($P < 0.05$). However, no significant difference was found in the total cholesterol (TC) levels between the fasting value and values at any nonfasting time points. The serum non-HDL-C level slightly increased from a fasting level of 4.29 mmol/L to nonfasting levels of 4.32, 4.38 and 4.34 mmol/L at 2, 4 and 6 h postprandially, respectively, and the difference reached statistical significance only at 4 and 6 h after breakfast ($P < 0.05$). No difference was observed in the fasting and nonfasting blood lipids between the two groups at baseline. After six weeks of Xuezhikang treatment, the patients had significantly lower fasting and nonfasting serum levels of LDL-C and non-HDL-C ($P < 0.05$) than at pretreatment. The LDL-C levels were reduced by 27.8%, 28.1%, 26.2% and 25.3% at 0, 2, 4 and 6 h, respectively, and the non-HDL-C levels were reduced by 27.6%, 28.7%, 29.0% and 28.0% at 0, 2, 4 and 6 h, respectively, after breakfast. No significant difference was found in the percent reductions in the LDL-C and non-HDL-C levels among the four different time points.

Conclusions: Six weeks of Xuezhikang treatment significantly decreased LDL-C and non-HDL-C levels, with similar percent reductions in the fasting and nonfasting states in CHD patients, indicating that the percent change in nonfasting LDL-C or non-HDL-C could replace that in the fasting state for evaluation of the efficacy of cholesterol control in CHD patients who are unwilling or unable to fast.

1 Introduction

According to the Chinese Cardiovascular Report 2019, eleven million Chinese individuals suffered from coronary heart disease (CHD). The mortality rate of CHD was 115.32/100000 in urban residents and 122.04/100000 in rural residents[1]. Compared with fasting hypertriglyceridemia, elevated fasting low-density lipoprotein cholesterol (LDL-C) levels are more closely associated with CHD, although evidence also shows that nonfasting hypertriglyceridemia is an independent risk factor for CHD[2].

Hypertriglyceridemia represents an increase in triglyceride (TG)-rich lipoproteins and their remnant-like particles (RLPs) in peripheral circulation. RLPs are considered to be as atherosclerotic as low-density

lipoprotein (LDL). Reducing LDL-C levels is the primary goal of cholesterol control, while the secondary goal is to control the level of non-high-density lipoprotein cholesterol (non-HDL-C)[3].

Atherogenesis is a nonfasting phenomenon[4]. Nonfasting lipids are initially detected after a high-fat meal, and more attention has been given to TG than to LDL-C or non-HDL-C[5, 6]. Recently, nonfasting blood lipids after a daily meal were reported in prospective studies with large populations[7]. Additionally, it was recommended that nonfasting blood samples should be routinely used to assess the lipid profiles in CHD patients on stable drug therapy or those who prefer nonfasting lipid detection[8, 9]. However, it remains unclear whether the detection of nonfasting blood lipids is appropriate during follow-up in CHD patients receiving their first treatment with statins.

After a daily meal, the levels of certain nonfasting cholesterol parameters are reduced[10]. The maximal mean reduction in the LDL-C or non-HDL-C level at 1–6 h after habitual food intake was only 0.2 mmol/L, which was considered nonsignificant in a population from Copenhagen[11]. However, Chinese subjects seemed to have a larger reduction in nonfasting LDL-C levels after a daily breakfast; the decrease was more than 0.3 mmol/L when the LDL-C level was calculated according to the Friedewald formula[12]. The nonfasting reduction in LDL-C may influence the evaluation of cholesterol control. Thus, it could be more appropriate to evaluate cholesterol control according to the percent reduction in LDL-C rather than the absolute LDL-C level in the nonfasting state.

Patients with type 2 diabetes, functional dyspepsia and CHD could benefit from dietary supplements, including red yeast rice[13–17]. As a natural statin, Xuezhikang, which is extracted from red yeast rice, has been recommended for the secondary prevention of CHD by the Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults (2016 revised edition)[16, 17]. Xuezhikang significantly improved the prognosis of Chinese patients with CHD by comprehensively regulating lipids, including by reducing nonfasting TG and lipoprotein(a) levels[18, 19], although its effect on nonfasting LDL-C and non-HDL-C levels was never mentioned. The high-fat breakfast with 800 kcal that was used in our previous studies[18, 20–23] had fewer calories than those used in other studies[24, 25], and this calorie level could be close to that of the habitual or daily breakfasts of some individuals. Thus, we aimed to explore the effects of short-term Xuezhikang treatment (1200 mg/d) on the nonfasting LDL-C and non-HDL-C levels of CHD patients who were accustomed to consuming a standard breakfast with 800 kcal and 50 g of fat and to compare the percent reduction in the LDL-C and non-HDL-C levels between the fasting and nonfasting states.

2 Materials And Methods

2.1 Study design and population:

The study protocol was approved by the Ethics Committee of Central South University (Hunan, China) and conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was provided by all the participants. This randomized, single-blind, placebo-controlled study was

performed in consecutive patients (n = 50). Patients who visited the second Xiangya Hospital between February 2001 and January 2002 for diagnostic evaluation or treatment were recruited. Enrolled patients were divided into the Xuezhikang and placebo groups at a 1:1 ratio according to an odd or even number that they randomly selected. Their dietary habits, nutrient intake, quantity of food intake, and daily activity were investigated by an open-question interview using a nutrition and health questionnaire[26, 27].

The inclusion criteria were as follows: men or women aged ≥ 18 y; New York Heart Association (NYHA) class I or II; CHD defined as a history of myocardial infarction and/or angiographically proven coronary artery stenosis $\geq 50\%$ with angina pectoris; subjects who tolerated a breakfast containing at least 800 kcal and 50 g of fat well.

The exclusion criteria were as follows: diabetes; thyroid diseases; liver and kidney diseases; malignancy; chronic consuming diseases, including malignant tumors, tuberculosis, chronic atrophic gastritis, severe trauma, burns, systemic lupus erythematosus, chronic suppurative infection and chronic blood loss; and the use of oral hypoglycemic or hypolipidemic agents.

All the patients had a four-week dietary advisory period. After at least 12 h of overnight fasting, the patients were given a standard breakfast with 800 kcal and 50 g of fat. Next, they either received Xuezhikang (1200 mg/d, 600 mg of cholestin per capsule; WBL Peking University Biotech Co., Ltd., China) or the placebo. After six weeks, the same standard breakfast was repeated. All the patients maintained a steady diet according to lipid-lowering dietary advice and accepted routine therapy, including aspirin, metoprolol, fosinopril and nitrates, during a six-week follow-up. No patient dropped out of the study during the six-week follow-up.

2.2 Standard breakfast and collection of blood samples

The standard breakfast in this study contained 800 kcal, 50 g of fat, 28 g of protein, and 60 g of carbohydrates. Blood samples were taken before and at 2, 4 and 6 h after the meal. During the 6-h test, the patients were not allowed to smoke, drink wine or eat any foods, with the option of consuming a little water. Vigorous exercise, including running and talking loudly, was forbidden, and only slow walking was allowed in a certain range of ward areas. Intravenous infusion was prohibited until the last blood sample was collected.

2.3 Lipid profile measurements

Blood samples were separated at 4 °C and stored at -20 °C. The serum levels of total cholesterol (TC), TG, and high-density lipoprotein cholesterol (HDL-C) were measured using an automatic biochemistry analyzer (Hitachi 7170, Tokyo, Japan) by a specialist who was blinded to this study. The LDL-C levels were calculated according to the Friedewald formula, i.e., $LDL-C = TC - HDL-C - TG/2.2$ (mmol/L), when the TG level was < 4.5 mmol/L; otherwise, it was measured by using a commercial direct method (Daiichi Pure Chemicals Co., Ltd. Tokyo, Japan). The cholesterol content in RLPs is termed remnant lipoprotein cholesterol (RC). The non-HDL-C and RC levels were estimated according to two formulas: non-HDL-C = $TC - HDL-C$ and $RC = non-HDL-C - LDL-C$, respectively.

2.4 Statistical analysis

The data were analyzed by using SPSS version 23.0 (IBM Corp, Armonk, NY, USA) and GraphPad Prism version 8.0.2 software (GraphPad Corp, San Diego, CA, USA). Quantitative variables are expressed as the mean $\pm$ SD, mean $\pm$ SEM or median and interquartile, and categorical variables are expressed as numbers or percentages (%). Intragroup comparisons among multiple time points were performed by one-way ANOVA for quantitative variables, and comparisons between two different time points were performed by the *t* test. When the quantitative variable did not meet the normality assumption of ANOVA or the Wilcoxon test for post hoc analysis, the Kruskal-Wallis test was performed. The difference in the intergroup means was analyzed by an independent *t* test. Categorical variables were compared using χ^2 analysis. The total area under the curve (tAUC) of each lipid parameter was estimated by using linear trapezoidal methods after breakfast[23]. Statistical significance was assumed at a two-tailed value of $P < 0.05$.

3 Results

3.1 Clinical characteristics of the recruited patients

The baseline characteristics, including sex, age, body mass index (BMI), heart rate, smoking habits, hypertension status, blood pressure, fasting blood glucose and creatinine, were roughly matched in the Xuezhikang (XZK) and control (CON) groups. Moreover, no significant difference was found in the fasting levels of TG, TC, LDL-C, HDL-C, non-HDL-C or RC between the groups (Table 1).

Table 1
Clinical characteristics of the patients.

	XZK group (n=25)	CON group (n=25)	<i>P</i> value
Age (years)	57.88 ± 5.69	58.64 ± 5.67	0.639
Male (n)	16	16	1.000
BMI (kg/m ²)	24.79 ± 2.16	24.91 ± 1.15	0.815
Smoker (n)	8	8	1.000
Hypertension (n)	12	12	1.000
SBP (mmHg)	125 ± 16	129 ± 22	0.526
DBP (mmHg)	81 ± 10	79 ± 7	0.432
Heart rate (1/min)	77 ± 7	77 ± 6	0.964
FBS (mmol/L)	5.46 ± 0.53	5.35 ± 0.44	0.437
Creatinine (μmmol/L)	108.17 ± 9.75	110.16 ± 7.37	0.421
TG (mmol/L)	2.00 ± 0.52	1.95 ± 0.34	0.686
TC (mmol/L)	5.47 ± 0.55	5.53 ± 0.40	0.628
LDL-C (mmol/L)	3.34 ± 0.41	3.33 ± 0.33	0.973
HDL-C (mmol/L)	1.15 ± 0.19	1.16 ± 0.13	0.767
Non-HDL-C (mmol/L)	4.32 ± 0.54	4.37 ± 0.35	0.685
RC (mmol/L)	0.98 ± 0.56	1.04 ± 0.36	0.672
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBS: fasting blood glucose; TG: triglyceride; TC: total plasma cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol.; RC: remnant lipoprotein cholesterol. The data are expressed as the mean ± SD or numbers.			

3.2 Effects of the 800-kcal breakfast on blood lipids

To analyze the changes in the nonfasting blood lipids in CHD patients at baseline, we pooled all the patient data (n = 50). No significant difference was found in the TC levels between the fasting and nonfasting states. The other two cholesterol parameters decreased significantly after breakfast ($P < 0.05$); although the reduction in nonfasting HDL-C was very mild, that in LDL-C was relatively obvious, especially 4 h postprandially. Additionally, the nonfasting non-HDL-C, TG and RC levels increased significantly after a high-fat breakfast ($P < 0.05$). However, the elevation of nonfasting non-HDL-C was very mild, while that of TG and RC was higher, particularly 4 h postprandially (Fig. 1A, 1B).

3.3 Changes in the nonfasting levels of blood lipids between the groups before and after six weeks.

The XZK and CON groups showed similar changes in nonfasting blood lipids after a high-fat breakfast compared to baseline. Six weeks of Xuezhikang treatment significantly increased the HDL-C levels and decreased the TG, TC, LDL-C, non-HDL-C and RC levels in both the fasting and nonfasting states ($P < 0.05$). However, no significant difference was found in the fasting levels of blood lipids and their nonfasting changes before and after six weeks in the CON group (Fig. 2A-2E).

Next, the tAUC was calculated to reflect overall changes in the nonfasting blood lipids within 6 h after a high-fat breakfast. No significant difference was found in the baseline tAUC for TG (18.0 vs. 17.9 h·mmol/L), TC (32.5 vs. 32.9 h·mmol/L), LDL-C (19.1 vs. 19.2 h·mmol/L), HDL-C (6.7 vs. 6.8 h·mmol/L), non-HDL-C (25.7 vs. 26.1 h·mmol/L) or RC (6.7 vs. 6.9 h·mmol/L) between the groups. After six weeks, the tAUC values for TG, TC, LDL-C, non-HDL-C, and RC were significantly lower, while that for HDL-C was significantly higher, than the baseline values in the XZK group ($P < 0.001$) but not in the CON group (Fig. 2F).

3.4 Comparisons of the fasting and nonfasting percent reductions in the LDL-C and non-HDL-C levels before and after six weeks in the XZK group

After six weeks of Xuezhikang treatment, the serum LDL-C level showed a reduction of 27.8% in the fasting state and 28.1%, 26.2% and 25.3% at 2, 4 and 6 h postprandially, respectively. The serum non-HDL-C levels showed a reduction of 27.6% in the fasting state and 28.7%, 29.0% and 28.0% at 2, 4 and 6 h postprandially, respectively. No significant difference was found in the percent reductions in the LDL-C and non-HDL-C levels between the fasting and nonfasting time points (Table 2).

Table 2
Comparisons of the percent reductions in the LDL-C and non-HDL-C levels among different time points after six weeks of Xuezhikang treatment (n=25)

	0 h	2 h	4 h	6 h	H	Pvalue
LDL-C	27.8% (21.2-33.8)	28.1% (16.4-38.0)	28.1% (16.4-38.0)	25.3% (16.7-37.0)	0.222	0.974
non-HDL-C	27.6% (22.0-33.9)	28.7% (22.9-35.5)	29.0% (23.7-36.0)	28.0% (22.2-33.3)	0.068	0.995
The data are expressed as the median and interquartile range.						

4 Discussion

Among all the cholesterol parameters, the LDL-C levels were reduced after breakfast. The TC levels were the most stable after breakfast, followed by the HDL-C and non-HDL-C levels, the changes did not exceed 0.1 mmol/L in this study. However, the RC level increased with increasing TG levels. Some scholars speculated that the reduced nonfasting LDL-C levels were likely induced by hemodilution due to fluid intake[11, 28]. Others attributed the decrease to biological rhythm and found that the LDL-C and HDL-C levels were significantly lower after breakfast until midnight than before breakfast[29]. Although the potential cause of the reduction in the nonfasting LDL-C levels in this study remained unclear, we should cautiously evaluate the cholesterol-lowering effect during follow-up if the LDL-C level was detected in a nonfasting state. For example, if the fasting LDL-C goal was < 1.8 mmol/L, it was difficult to decide whether a nonfasting LDL-C level of 1.65 mmol/L reached the target. Thus, evaluating the nonfasting LDL-C level according to the fasting LDL-C goal may be inappropriate.

With the update of the Chinese and Western guidelines for the management of dyslipidemia in adults, evaluation of the percent reduction in LDL-C level has become increasingly important[16, 30, 31]. For a nonnegligible reduction in LDL-C levels after breakfast in this study, the percent reduction was calculated to compare the effects of Xuezhikang on the LDL-C levels between the fasting level and levels at the nonfasting time points. After six weeks, the LDL-C levels presented similar changes at four different time points, with a percent reduction between 25.3% and 28.2%. More importantly, no significant difference was found in the percent reductions in the LDL-C level among the four different time points. Thus, if the LDL-C level was detected after a standard breakfast in the first visit in one patient, it can be detected repeatedly after an identical breakfast at the second visit six weeks later. That is, the nonfasting LDL-C levels could be used to evaluate cholesterol control in unstable patients. Considering the CHD patients who regularly consumed a daily breakfast with ≥ 800 kcal and ≥ 50 g of fat, the standard breakfast in this study can be regarded as a customary breakfast. Thus, the findings from this study could apply to CHD patients with similar dietary habits.

In the present study, the percent reduction in the LDL-C level was less than 27.8%, which was very close to that reported by other studies, including 28.5% by the China Coronary Secondary Prevention Study (CCSPS) and 27% by a Food and Drug Administration Phase II clinical study[32]. With every 1% decrease in the LDL-C level, the relative risk of cardiovascular events is reduced by 1%[33]. Because Chinese patients with CHD had lower baseline LDL-C levels than Western patients[1, 34, 35], a nearly 30% reduction in LDL-C induced by a six-week Xuezhikang treatment lowered the mean fasting LDL-C level to < 2.6 mmol/L in 76% of CHD patients, representing the LDL-C goal recommended by the guidelines of the National Cholesterol Education Program in 2002[36]. Considering that this study was completed in 2002, a nearly 30% reduction in LDL-C level was clinically significant at that time.

Compared with the LDL-C levels, the non-HDL-C levels changed slightly after breakfast in this study, which is likely related to the obvious increase in RC levels. The non-HDL-C level includes the LDL-C level and RC level at each time point. The percent reduction in the non-HDL-C level was slightly greater than

that in the LDL-C level at each nonfasting time point, likely because Xuezhikang inhibited the increase in the nonfasting TG and RC levels. Similar to the LDL-C level, the non-HDL-C level also showed very similar percent reductions among the four different time points. This finding indicates that the non-HDL-C levels can be detected and evaluated in the nonfasting state during follow-up for those who are unwilling or unable to maintain the fasting state[30, 37, 38].

The mechanism by which Xuezhikang reduces blood lipids is complex. Xuezhikang contains natural lovastatin (i.e., monacolin K) and 12 other natural monacolins (24 mg in each Xuezhikang capsule) that are statin homologs. Additionally, it comprises other ingredients, such as sterols[39]. Compared with 10 mg of lovastatin, 1200 mg of Xuezhikang showed more potent effects in lowering cholesterol and the TG levels[40]. CCSPS demonstrated that Xuezhikang significantly decreased the risk of cardiovascular events and total mortality by 30% and 33%, respectively, in Chinese patients with CHD, a finding that was not completely explained by the decrease in LDL-C induced by natural statins in Xuezhikang[32]. Other components of Xuezhikang, such as unsaturated fatty acids, sterols and flavonoids, may also play essential roles in cardiovascular protection[39]. New evidence has shown that unsaturated fatty acids not only display antioxidative and TG-lowering effects but also further reduce cardiovascular events based on statin treatment[41–43].

The safety of Xuezhikang was a concern[44]. However, according to a recent meta-analysis of 53 randomized controlled trials with 8,535 patients (4,437 in the red yeast rice treatment arm and 4,303 in the control arm), the use of monacolin K is not associated with an increased risk of muscular adverse events (OR: 0.94; 95% CI: 0.53–1.65)[45]. In the real world, some patients could take Xuezhikang because of their intolerance to synthetic statins[46]. Xuezhikang should be taken as two capsules orally after meals twice a day[47]. Dual lipid-lowering therapy with statins and a non-statin agent has promoted coronary atherosclerosis regression and improved cardiovascular outcomes in CHD patients[48]. Pharmacological inhibition of cholesterol absorption (with ezetimibe) and PCSK9 activity (with evolocumab or alirocumab) may show a better therapeutic effect on LDL-C metabolism in statin-treated patients[49].

This study has several limitations. First, this study was a single-blind clinical observational study with a small sample size. According to the previous recommendations of international guidelines around 2000[36], statin treatment was initiated after ineffective lifestyle interventions in CHD patients, explaining why approximately half of the participants in this study did not receive Xuezhikang treatment immediately after the CHD diagnosis. A randomized, double-blind clinical trial with a larger sample is warranted in the future. Second, more relevant lipid profiles and inflammatory markers should be detected throughout the day in the future, although a certain type of breakfast may trigger the fluctuation of inflammation and metabolic parameters that are linked to biological rhythms.

In conclusion, six weeks of Xuezhikang treatment significantly decreased LDL-C and non-HDL-C levels, with similar percent reductions in fasting and nonfasting states in CHD patients, indicating that the

percent change in nonfasting LDL-C or non-HDL-C could replace that in the fasting state for evaluation of the efficacy of cholesterol control in CHD patients who are unwilling or unable to fast.

Abbreviations

CHD: coronary heart disease; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; non-high-density lipoprotein cholesterol (non-HDL-C); TG: triglyceride; RLP: remnant-like particle; RC: remnant lipoprotein cholesterol; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBS: fasting blood sugar; CCSPS: China Coronary Secondary Prevention Study.

Declarations

Ethics approval and consent to participate

All participants provided written consent before entering the study according to the regulations of the Ethics Committee of the Second Xiangya Hospital of Central South University.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing Interests

The authors have declared that no conflicts of interest exist.

Funding

The study was supported by the Fundamental Research Funds for the Central Universities of Central South University [grant numbers 2020zzts882] and the National Natural Science Foundation of China [grant numbers 81270956 and 81470577].

Author Contributions

Li-Yuan Zhu and Ling Liu wrote the manuscript and reviewed the literature. Ling Liu and Shui-Ping Zhao designed the study and collected the data. Li-Yuan Zhu, Xing-Yu Wen, Qun-Yan Xiang, Li-Ling Guo and Jin Xu analyzed the data and prepared the figures and tables. All authors approved the final manuscript.

Acknowledgments

We thank the patients for their participation in this study.

References

1. Group CCDRW: **Summary of Chinese Cardiovascular Disease Report 2019.** *Chinese Circulation Journal* 2020, **35**:833-854.
2. Masuda D, Yamashita S: **Postprandial Hyperlipidemia and Remnant Lipoproteins.** *J Atheroscler Thromb* 2017, **24**:95-109.
3. European Association for Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, et al: **ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).** *Eur Heart J* 2011, **32**:1769-1818.
4. Zilversmit DB: **Atherogenesis: a postprandial phenomenon.** *Circulation* 1979, **60**:473-485.
5. Nakamura A, Monma Y, Kajitani S, Kozu K, Ikeda S, Noda K, Nakajima S, Endo H, Takahashi T, Nozaki E: **Different postprandial lipid metabolism and insulin resistance between non-diabetic patients with and without coronary artery disease.** *J Cardiol* 2015, **66**:435-444.
6. Gill JM, Caslake MJ, McAllister C, Tsofliou F, Ferrell WR, Packard CJ, Malkova D: **Effects of short-term detraining on postprandial metabolism, endothelial function, and inflammation in endurance-trained men: dissociation between changes in triglyceride metabolism and endothelial function.** j.gill@bio.gla.ac.uk. *J Clin Endocrinol Metab* 2003, **88**:4328-4335.
7. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG: **Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up.** *J Intern Med* 2011, **270**:65-75.
8. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Boren J, et al: **Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.** *Clin Chem* 2016, **62**:930-946.
9. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Boren J, et al: **Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint**

- consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. *Eur Heart J* 2016, **37**:1944-1958.
10. Tian F, Xiang QY, Zhang MY, Chen YQ, Lin QZ, Wen T, Liu L: **Changes in non-fasting concentrations of blood lipids after a daily Chinese breakfast in overweight subjects without fasting hypertriglyceridemia.** *Clin Chim Acta* 2019, **490**:147-153.
 11. Langsted A, Nordestgaard BG: **Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study.** *Clin Chem* 2011, **57**:482-489.
 12. Lin QZ, Chen YQ, Guo LL, Xiang QY, Tian F, Wen T, Liu L: **Comparison of non-fasting LDL-C levels calculated by Friedewald formula with those directly measured in Chinese patients with coronary heart disease after a daily breakfast.** *Clin Chim Acta* 2019, **495**:399-405.
 13. Namazi N, Khodamoradi K, Khamechi SP, Heshmati J, Ayati MH, Larijani B: **The impact of cinnamon on anthropometric indices and glycemic status in patients with type 2 diabetes: A systematic review and meta-analysis of clinical trials.** *Complement Ther Med* 2019, **43**:92-101.
 14. Agah S, Akbari A, Heshmati J, Sepidarkish M, Morvaridzadeh M, Adibi P, Mazidi M, Farsi F, Ofori-Asenso R, Talley NJ, Feinle-Bisset C: **Systematic review with meta-analysis: Effects of probiotic supplementation on symptoms in functional dyspepsia.** *Journal of Functional Foods* 2020, **68**.
 15. Akbari-Fakhrabadi M, Heshmati J, Sepidarkish M, Shidfar F: **Effect of sumac (*Rhus Coriaria*) on blood lipids: A systematic review and meta-analysis.** *Complement Ther Med* 2018, **40**:8-12.
 16. Chu JR, Gao RL, Zhao SP, Lu GP, Zhao D, Li JJ: **Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (revised in 2016).** *Chinese Circulation Journal* 2016, **31**:937-953.
 17. Authors/Task Force M, Guidelines ESCCfP, Societies ESCNC: **2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.** *Atherosclerosis* 2019, **290**:140-205.
 18. Zhao SP, Liu L, Cheng YC, Li YL: **Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease.** *Atherosclerosis* 2003, **168**:375-380.
 19. L L, SP Z, YC C, YL L: **Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease.** *Clinical chemistry* 2003, **49**:1347-1352.
 20. Zhao SP, Liu L, Cheng YC, Shishehbor MH, Liu MH, Peng DQ, Li YL: **Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease.** *Circulation* 2004, **110**:915-920.
 21. Zhao SP, Liu L, Gao M, Zhou QC, Li YL, Xia B: **Impairment of endothelial function after a high-fat meal in patients with coronary artery disease.** *Coron Artery Dis* 2001, **12**:561-565.
 22. Ling L, Zhao SP, Gao M, Zhou QC, Li YL, Xia B: **Vitamin C preserves endothelial function in patients with coronary heart disease after a high-fat meal.** *Clin Cardiol* 2002, **25**:219-224.
 23. Xu J, Chen YQ, Zhao SP, Liu L: **Determination of optimal cut-off points after a high-fat meal corresponding to fasting elevations of triglyceride and remnant cholesterol in Chinese subjects.**

24. Vogel RA, Corretti MC, Plotnick GD: **Effect of a single high-fat meal on endothelial function in healthy subjects.** *Am J Cardiol* 1997, **79**:350-354.
25. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM, Jr.: **Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia.** *Proc Natl Acad Sci U S A* 1983, **80**:1449-1453.
26. Parmenter K, Wardle J: **Development of a general nutrition knowledge questionnaire for adults.** *Eur J Clin Nutr* 1999, **53**:298-308.
27. Turconi G, Celsa M, Rezzani C, Biino G, Sartirana MA, Roggi C: **Reliability of a dietary questionnaire on food habits, eating behaviour and nutritional knowledge of adolescents.** *Eur J Clin Nutr* 2003, **57**:753-763.
28. Langsted A, Freiberg JJ, Nordestgaard BG: **Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction.** *Circulation* 2008, **118**:2047-2056.
29. Miida T, Nakamura Y, Mezaki T, Hanyu O, Maruyama S, Horikawa Y, Izawa S, Yamada Y, Matsui H, Okada M: **LDL-cholesterol and HDL-cholesterol concentrations decrease during the day.** *Ann Clin Biochem* 2002, **39**:241-249.
30. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al: **2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.** *J Am Coll Cardiol* 2019, **73**:e285-e350.
31. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al: **2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.** *Eur Heart J* 2020, **41**:111-188.
32. Li JJ, Lu ZL, Kou WR, Bolli R, Chen Z, Wu YF, Yu XH, Zhao YC: **Impact of long-term Xuezhikang therapy on cardiovascular events in high-risk patients with nonspecific, preexisting abnormal liver tests: a post-hoc analysis from Chinese Coronary Secondary Prevention Study (CCSPS).** *Int J Cardiol* 2012, **154**:362-365.
33. Group HPSC: **MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial.** *The Lancet* 2002, **360**:7-22.
34. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al: **Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.** *Circulation* 2020, **141**:e139-e596.
35. Zhao S, Peng D: **Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomized, double-blind, active-controlled study.** *Curr Med Res Opin* 2018, **34**:227-235.

36. De Backer G: **European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts).** *European Heart Journal* 2003, **24**:1601-1610.
37. Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J, Jr., Grover S, Gupta M, et al: **2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.** *Can J Cardiol* 2016, **32**:1263-1282.
38. Su X, Kong Y, Peng D: **Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol.** *Lipids Health Dis* 2019, **18**:134.
39. Cicero AFG, Fogacci F, Banach M: **Red Yeast Rice for Hypercholesterolemia.** *Methodist Debaquey Cardiovasc J* 2019, **15**:192-199.
40. Chen CH, Uang YS, Wang ST, Yang JC, Lin CJ: **Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin.** *Evid Based Complement Alternat Med* 2012, **2012**:127043.
41. Sepidarkish M, Akbari-Fakhrabadi M, Daneshzad E, Yavari M, Rezaeinejad M, Morvaridzadeh M, Heshmati J: **Effect of omega-3 fatty acid plus vitamin E Co-Supplementation on oxidative stress parameters: A systematic review and meta-analysis.** *Clin Nutr* 2020, **39**:1019-1025.
42. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Jr., Juliano RA, Jiao L, Granowitz C, et al: **Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.** *N Engl J Med* 2019, **380**:11-22.
43. Darvish Damavandi R, Mousavi SN, Shidfar F, Mohammadi V, Rajab A, Hosseini S, Heshmati J: **Effects of Daily Consumption of Cashews on Oxidative Stress and Atherogenic Indices in Patients with Type 2 Diabetes: A Randomized, Controlled-Feeding Trial.** *Int J Endocrinol Metab* 2019, **17**:e70744.
44. Elmas E, Kalsch T, Suvajac N, Leweling H, Neumaier M, Dempfle CE, Borggrefe M: **Activation of coagulation during alimentary lipemia under real-life conditions.** *Int J Cardiol* 2007, **114**:172-175.
45. Fogacci F, Banach M, Mikhailidis DP, Bruckert E, Toth PP, Watts GF, Reiner Z, Mancini J, Rizzo M, Mitchenko O, et al: **Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials.** *Pharmacol Res* 2019, **143**:1-16.
46. Committee of Cardio-Cerebro-Vascular Diseases of Gerontological Society of C, Working Group of Chinese Expert Consensus on the Use of X: **[Chinese expert consensus on the use of Xuezhikang (2017 revised edition)].** *Zhonghua Nei Ke Za Zhi* 2018, **57**:97-100.
47. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM, Chinese Coronary Secondary Prevention Study G, Li S: **Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.** *Am J Cardiol* 2008, **101**:1689-1693.

48. Gragnano F, Calabro P: **Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies.** *Atherosclerosis* 2018, **269**:219-228.
49. Cesaro A, Bianconi V, Gragnano F, Moscarella E, Fimiani F, Monda E, Scudiero O, Limongelli G, Pirro M, Calabro P: **Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9).** *Genetics, mutations, expression, and perspective for long-term inhibition.* *Biofactors* 2020, **46**:367-380.

Figures

Figure 1

Effect of a high-fat meal on the nonfasting levels of blood lipids in all the patients at baseline (n=50). (A) Changes in the nonfasting serum levels of TC, LDL-C, and HDL-C after a high-fat meal at baseline. (B) Changes in the nonfasting serum levels of TG, non-HDL-C, and RC after a high-fat meal at baseline. * P < 0.05 compared with the fasting level of the same parameter. The data are expressed as the mean ± SEM. TC: total cholesterol (A); LDL-C: low-density lipoprotein cholesterol (B); HDL-C: high-density lipoprotein cholesterol (C); non-HDL-C: non-high-density lipoprotein cholesterol (D); TG: triglyceride (E); RC: remnant cholesterol (F).

Figure 1

Effect of a high-fat meal on the nonfasting levels of blood lipids in all the patients at baseline (n=50). (A) Changes in the nonfasting serum levels of TC, LDL-C, and HDL-C after a high-fat meal at baseline. (B) Changes in the nonfasting serum levels of TG, non-HDL-C, and RC after a high-fat meal at baseline. * $P < 0.05$ compared with the fasting level of the same parameter. The data are expressed as the mean $\pm$ SEM. TC: total cholesterol (A); LDL-C: low-density lipoprotein cholesterol (B); HDL-C: high-density lipoprotein cholesterol (C); non-HDL-C: non-high-density lipoprotein cholesterol (D); TG: triglyceride (E); RC: remnant cholesterol (F).

Figure 2

Effect of XZK treatment on the nonfasting levels of blood lipids after a high-fat meal. (A-F) Changes in the fasting and nonfasting levels of blood lipids between the two groups before and after 6 w. * $P < 0.05$ when compared with the fasting level in the XZK group. # $P < 0.05$ when compared with the CON group at the same time point after six weeks. The data are expressed as the mean $\pm$ SEM. (G) Comparisons of the tAUC for blood lipids after a high-fat meal before and after six weeks in the two groups. † $P < 0.001$ when compared with the CON group after six weeks. ‡ $P < 0.001$ when compared with the XZK group at baseline. The data are expressed as the mean $\pm$ SEM.

Figure 2

Effect of XZK treatment on the nonfasting levels of blood lipids after a high-fat meal. (A-F) Changes in the fasting and nonfasting levels of blood lipids between the two groups before and after 6 w. * $P < 0.05$ when compared with the fasting level in the XZK group. # $P < 0.05$ when compared with the CON group at the same time point after six weeks. The data are expressed as the mean $\pm$ SEM. (G) Comparisons of the tAUC for blood lipids after a high-fat meal before and after six weeks in the two groups. † $P < 0.001$ when compared with the CON group after six weeks. ‡ $P < 0.001$ when compared with the XZK group at baseline. The data are expressed as the mean $\pm$ SEM.